Robbins LLP Invites Altimmune Stockholders to Lead Class Action Lawsuit Against the Company

In a recent development, Robbins LLP has announced the opportunity for stockholders of Altimmune, Inc. (NASDAQ: ALT) to lead a class action lawsuit concerning alleged misconduct by the company. This follows a class action filed for individuals who acquired Altimmune securities between August 10, 2023, and June 25, 2025, coinciding with a key trial that impacted the company’s market value significantly.

Overview of the Situation

Altimmune is a biopharmaceutical company currently in the clinical trial phase, with a focus on developing treatments for obesity, metabolic conditions, and liver diseases. The legal action stems from a failure to achieve significant results in the company's recent IMPACT Phase 2b MASH trial of Pemvidutide, a treatment intended for metabolic associated fatty liver disease. During the trial period, company representatives expressed strong optimism regarding the outcomes, which were ultimately disappointing due to a higher-than-anticipated placebo effect.

On June 26, 2025, Altimmune disclosed the trial results, leading to a drastic drop in the company’s stock price from $7.71 per share to only $3.61, marking a staggering decline of over 53% within a single day. This considerable loss has prompted Robbins LLP to advise stockholders of their potential right to seek accountability through a class action lawsuit.

The Allegations

The essence of the allegations involves claims that Altimmune misled its investors regarding the potential success of its MASH trial. Robbins LLP states that the company provided overly optimistic projections about the trial's topline results, which ultimately proved to be unfounded. The complaint against Altimmune indicates that during the class period, the company's leadership consistently conveyed their positive expectations surrounding the trial's outcomes. However, the disappointing results highlighted the disconnect between management's assurances and the actual performance of the trial.

How to Participate

For affected shareholders wishing to participate in the class action or serve as lead plaintiff, they are encouraged to submit their paperwork by October 6, 2025. The lead plaintiff will act on behalf of all class members, directing the litigation process. Notably, shareholders do not need to actively participate in the case to benefit from potential recoveries, as they can remain absent class members if they choose. Robbins LLP continues to provide resources to facilitate the participation of affected investors, emphasizing that all representation will be on a contingency-fee basis, meaning clients do not incur any upfront fees or expenses.

About Robbins LLP

Since its establishment in 2002, Robbins LLP has been recognized as a leading firm in shareholder rights litigation. The firm is dedicated to helping investors recover losses and enhance corporate governance standards. Throughout its history, Robbins LLP has successfully held executives accountable for their actions and provided a voice to shareholders facing inequities.

For stockholders looking for additional information or wishing to remain updated about the class action and further developments involving Altimmune, Robbins LLP encourages sign-ups for their Stock Watch service. This platform offers alerts when corporate misconduct occurs and helps ensure that investors are kept informed.

In conclusion, the ongoing situation with Altimmune reflects the importance of transparency and accountability in the biopharmaceutical industry. Investors are reminded to stay vigilant and informed regarding the companies they support, especially in light of significant trial results that can affect stock performance substantially.